Yu-Wei Chen1, Brandon A Mahal2, Vinayak Muralidhar3, Michelle Nezolosky1, Clair J Beard3, Robert B Den4, Felix Y Feng5, Karen E Hoffman6, Neil E Martin3, Peter F Orio3, Paul L Nguyen7. 1. Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts. 2. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 3. Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 4. Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania. 5. Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan. 6. Department of Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: pnguyen@LROC.harvard.edu.
Abstract
PURPOSE: Although the association between higher hospital volume and improved outcomes has been well-documented in surgery, there is little data about whether this effect exists for radiation-treated patients. We investigated whether treatment at a radiation facility that treats a high volume of prostate cancer patients is associated with improved survival for men with high-risk prostate cancer. METHODS AND MATERIALS: We used the National Cancer Database (NCDB) to identity patients diagnosed with prostate cancer from 2004 to 2006. The radiation case volume (RCV) of each hospital was based on its number of radiation-treated prostate cancer patients. We used propensity-score based analysis to compare the overall survival (OS) of high-risk prostate cancer patients in high versus low RCV hospitals. Primary endpoint is overall survival. Covariates adjusted for were tumor characteristics, sociodemographic factors, radiation type, and use of androgen deprivation therapy (ADT). RESULTS: A total of 19,565 radiation-treated high-risk patients were identified. Median follow-up was 81.0 months (range: 1-108 months). When RCV was coded as a continuous variable, each increment of 100 radiation-managed patients was associated with improved OS (adjusted hazard ratio [AHR]: 0.97; 95% confidence interval [CI]: 0.95-0.98; P<.0001) after adjusting for known confounders. For illustrative purposes, when RCV was dichotomized at the 80th percentile (43 patients/year), high RCV was associated with improved OS (7-year overall survival 76% vs 74%, log-rank test P=.0005; AHR: 0.91, 95% CI: 0.86-0.96, P=.0005). This association remained significant when RCV was dichotomized at 75th (37 patients/year), 90th (60 patients/year), and 95th (84 patients/year) percentiles but not the 50th (19 patients/year). CONCLUSIONS: Our results suggest that treatment at centers with higher prostate cancer radiation case volume is associated with improved OS for radiation-treated men with high-risk prostate cancer.
PURPOSE: Although the association between higher hospital volume and improved outcomes has been well-documented in surgery, there is little data about whether this effect exists for radiation-treated patients. We investigated whether treatment at a radiation facility that treats a high volume of prostate cancerpatients is associated with improved survival for men with high-risk prostate cancer. METHODS AND MATERIALS: We used the National Cancer Database (NCDB) to identity patients diagnosed with prostate cancer from 2004 to 2006. The radiation case volume (RCV) of each hospital was based on its number of radiation-treated prostate cancerpatients. We used propensity-score based analysis to compare the overall survival (OS) of high-risk prostate cancerpatients in high versus low RCV hospitals. Primary endpoint is overall survival. Covariates adjusted for were tumor characteristics, sociodemographic factors, radiation type, and use of androgen deprivation therapy (ADT). RESULTS: A total of 19,565 radiation-treated high-risk patients were identified. Median follow-up was 81.0 months (range: 1-108 months). When RCV was coded as a continuous variable, each increment of 100 radiation-managed patients was associated with improved OS (adjusted hazard ratio [AHR]: 0.97; 95% confidence interval [CI]: 0.95-0.98; P<.0001) after adjusting for known confounders. For illustrative purposes, when RCV was dichotomized at the 80th percentile (43 patients/year), high RCV was associated with improved OS (7-year overall survival 76% vs 74%, log-rank test P=.0005; AHR: 0.91, 95% CI: 0.86-0.96, P=.0005). This association remained significant when RCV was dichotomized at 75th (37 patients/year), 90th (60 patients/year), and 95th (84 patients/year) percentiles but not the 50th (19 patients/year). CONCLUSIONS: Our results suggest that treatment at centers with higher prostate cancer radiation case volume is associated with improved OS for radiation-treated men with high-risk prostate cancer.
Authors: Alexander L Chin; Everett J Moding; Sarah S Donaldson; Iris C Gibbs; Scott G Soltys; Susan M Hiniker; Erqi L Pollom Journal: Neuro Oncol Date: 2018-07-05 Impact factor: 12.300
Authors: Nicholas C J Lee; Jacqueline R Kelly; Yi An; Henry S Park; Benjamin L Judson; Barbara A Burtness; Zain A Husain Journal: Cancer Date: 2019-02-12 Impact factor: 6.860
Authors: Vivek Verma; Pamela K Allen; Charles B Simone; Hiram A Gay; Steven H Lin Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-01-01 Impact factor: 6.223
Authors: Mohamed H Kamel; Milan Bimali; Mahmoud I Khalil; Ehab Eltahawy; LJoseph Su; Nabil K Bissada; Rodney Davis Journal: Int Urol Nephrol Date: 2019-03-06 Impact factor: 2.370
Authors: Matthew Koshy; David J Sher; Michael Spiotto; Zain Husain; Herb Engelhard; Konstantin Slavin; Martin K Nicholas; Ralph R Weichselbaum; Chad Rusthoven Journal: J Neurooncol Date: 2017-08-23 Impact factor: 4.130
Authors: Johnny Kao; Amanda Zucker; Jonathan Timmins; Shankar Taramangalam; Jeffrey Pettit; Aaron J Woodall; Edward Loizides; Andrew T Wong Journal: Mol Clin Oncol Date: 2017-06-08
Authors: Sriram Venigalla; Kevin T Nead; Ronnie Sebro; David M Guttmann; Sonam Sharma; Charles B Simone; William P Levin; Robert J Wilson; Kristy L Weber; Jacob E Shabason Journal: Int J Radiat Oncol Biol Phys Date: 2017-12-21 Impact factor: 7.038
Authors: Tyler Abarca; Yubo Gao; Varun Monga; Munir R Tanas; Mohammed M Milhem; Benjamin J Miller Journal: J Surg Oncol Date: 2018-04-06 Impact factor: 3.454
Authors: Evan M Graboyes; Mark A Ellis; Hong Li; John M Kaczmar; Anand K Sharma; Eric J Lentsch; Terry A Day; Chanita Hughes Halbert Journal: Cancer Date: 2018-06-22 Impact factor: 6.860